Introduction {#section1-1534735418805149}
============

According to the Global Burden of Disease Report, cancer is the second leading cause of death worldwide. In the past 10 years, the incidence of cancer has increased by 33%. Thus, cancer poses a great threat to the health of humanity.^[@bibr1-1534735418805149]^ Cancer-related fatigue (CRF) and fear of recurrence (FOR) are common seriously disturbing problems faced by cancer survivors.^[@bibr2-1534735418805149][@bibr3-1534735418805149]-[@bibr4-1534735418805149]^ CRF is accompanied by lack of strength, depressed mood, and sleep disorders, which lead to reduced physical, social, cognitive, and vocational function. Moreover, CRF can easily be overlooked by medical staff, resulting in delayed treatment.^[@bibr5-1534735418805149],[@bibr6-1534735418805149]^

Cancer recurrence is the most difficult stage during the course of the disease. FOR can lead to emotional distress and cognitive and behavioral disorders that can affect recovery. FOR does not decrease as the treatment ends or as the survival duration increases. Patients with a good prognosis or a low risk of recurrence remain fearful or worried, which severely affects their quality of life (QOL) and results in burdens to the individual, family, and society.^[@bibr7-1534735418805149]^ Approximately one third of cancer survivors suffer from the long-term impact of CRF,^[@bibr8-1534735418805149]^ and more than 70% are currently experiencing FOR.^[@bibr9-1534735418805149],[@bibr10-1534735418805149]^

Cancer-related physical and physiological disorders can cause autonomic nervous system (ANS) dysfunction. Compared with healthy individuals, cancer survivors generally have lower heart rate variability (HRV).^[@bibr11-1534735418805149][@bibr12-1534735418805149]-[@bibr13-1534735418805149]^ HRV can be used to monitor the regulatory functions and status of the human ANS.^[@bibr13-1534735418805149]^ In clinical practice, HRV has not only been adopted as a diagnostic indicator of ANS dysfunction^[@bibr14-1534735418805149]^ but has also been used as a marker for cancer-related distress and recovery status.^[@bibr12-1534735418805149]^

Cancer survivors must tolerate pain caused by the disease and are also under greater psychological pressures than other people. The influence of the mind-body interaction leads to decreased physical functions and can even diminish the effects of medical treatments. In recent years, more than 75% of cancer survivors have undergone traditional cancer treatment in combination with complementary and alternative medicine to reduce the disturbing symptoms of cancer. This integrative treatment has yielded improved effects and increased QOL.^[@bibr15-1534735418805149],[@bibr16-1534735418805149]^ Some studies have shown that 12 weeks of Qigong exercise (QE) intervention can reduce fatigue, anxiety, and depression and promote quality of sleep in breast and prostate cancer patients.^[@bibr17-1534735418805149][@bibr18-1534735418805149]-[@bibr19-1534735418805149]^ Therefore, this study adopted "Guide health-preserving Qigong" as a QE intervention. QE, which is widely applied in complementary and alternative medicine, can increase blood circulation, improve lung and heart function, regulate homeostasis, moderate emotions, and allow self-healing.^[@bibr20-1534735418805149][@bibr21-1534735418805149]-[@bibr22-1534735418805149]^

Some research has indicated that participation in stress management (SM) training courses may promote life value, self-efficacy, and QOL and may reduce the physical and mental symptoms of cancer patients.^[@bibr3-1534735418805149],[@bibr6-1534735418805149],[@bibr23-1534735418805149]^ SM helps cancer survivors realize the value of life, seek self-development, and improve their interpersonal relationships.^[@bibr3-1534735418805149],[@bibr23-1534735418805149],[@bibr24-1534735418805149]^ Hence, QE and SM can both promote the self-regulation functions of the body, improve HRV, and restore balance to the ANS.^[@bibr11-1534735418805149],[@bibr25-1534735418805149][@bibr26-1534735418805149]-[@bibr27-1534735418805149]^ Furthermore, QE and SM can alleviate symptoms such as fatigue, anxiety, depression, and sleep disorders and can thus improve the QOL of cancer survivors.^[@bibr18-1534735418805149],[@bibr27-1534735418805149][@bibr28-1534735418805149][@bibr29-1534735418805149][@bibr30-1534735418805149]-[@bibr31-1534735418805149]^ After regular treatments, providing cancer survivors with immediate and effective interventions during the recovery stage to assist in reducing distress due to the mental and physical symptoms of the disease is necessary and urgent. The results of this study can assist cancer survivors in maintaining recovery activities and restoring QOL and can provide a reference for care following treatment for cancer.

Methods {#section2-1534735418805149}
=======

A longitudinal study with an interventional research design was conducted separately in 2 cancer centers in northern and southern Taiwan. The participants were randomly assigned to experimental groups E1 (QE) or E2 (SM) or to the control group. A 12-week intervention and a 3-month follow-up evaluation were employed in this study.

Participants and Study Design {#section3-1534735418805149}
-----------------------------

### Eligibility Criteria {#section4-1534735418805149}

The inclusion criteria for the participants were cancer survivors who (1) had completed regular treatment, including surgery, chemotherapy, radiation therapy, and target therapy, at least 1 month prior to the beginning of the study; (2) had experienced no cancer recurrence; and (3) had received hormone replacement therapy for breast cancer. The exclusion criteria were (1) participants with a diagnosis of stage IV cancer; and (2) participants with moderate or severe arrhythmia.

### Sample Size {#section5-1534735418805149}

The medium effect sizes recommended in relevant studies before and after implementing intervention and during follow-up were adopted for the sample calculation.^[@bibr18-1534735418805149]^ Repeated-measures analysis of variance (ANOVA) was performed using G\*Power software. The effect size was 0.3, the α was 0.05, and the power was 0.8. The expected dropout rate was 25%. Thus, a minimum of 98 participants was required for this study. There were 99 qualified participants recruited from the 2 cancer centers. The participants were randomly assigned to the QE group (E1 = 33), the SM group (E2 = 33), or the control group (n = 33). However, only 80 participants completed the intervention. Twenty-nine of these were in the E1 group (n = 29), 25 were in the E2 group (n = 25), and 26 were in the control group (n = 26; [Figure 1](#fig1-1534735418805149){ref-type="fig"}).

![CONSORT flow diagram of this study.](10.1177_1534735418805149-fig1){#fig1-1534735418805149}

### Study Design {#section6-1534735418805149}

Prior to the intervention, a 2-hour basic nutrition management course was provided to all participants. Subsequently, the E1 group received QE training, and the E2 group received SM training. The intervention was conducted once a week for 2 hours for a total of 12 weeks. No intervention was performed in the control group; the participants in that group maintained their daily routines. Data for overall CRF, FOR, the QOL questionnaire, and HRV were collected at 3 time points at 3-month intervals. The time points used to assess the potential improvement were baseline (T0), 12 weeks postintervention (T1), and 3-month follow-up (T2).

Outcome Measures {#section7-1534735418805149}
----------------

A pilot study was conducted by performing pretesting on 99 cancer patients in outpatient clinics to verify the reliability and validity of the CRF and FOR scales.

### CRF Scale {#section8-1534735418805149}

The CRF scale was designed based on the diagnosis criteria of the ICD-10 (International Classification of Diseases, Tenth Revision) and included 15 items.^[@bibr32-1534735418805149]^ A 5-point Likert-type scale was utilized for all items used to evaluate the degree of fatigue of cancer survivors within the past 2 weeks. Higher scores indicated severe CRF. Exploratory factor analysis was adopted. Factor loadings were evaluated using the maximum likelihood method; the Kaiser-Meyer-Olkin value was 0.839. Bartlett's test of sphericity yielded χ^2^ = 541.686 (*P* \< .001). Finally, principal component analysis with axis rotation was applied to examine the construct validity of the scale. Factors with eigenvalues \>1 were extracted, and only 10 questions remained after multiple examinations. The 10 questions can be categorized into 3 domains: lifestyle function, mind-body function, and sleep condition. The accumulated variation was 74.998%. The overall Cronbach's α of the internal consistency reliability of the scale was 0.878, suggesting very good reliability and effectiveness. Moreover, within each domain, the correlation coefficient of each item was greater than 0.500 after removing the question, indicating good reliability and effectiveness of the questionnaire as a measurement tool for evaluating CRF ([Table 1](#table1-1534735418805149){ref-type="table"}).

###### 

A Pilot Study for Factor Analysis of Cancer-Related Fatigue and Fear of Recurrence Scales.

![](10.1177_1534735418805149-table1)

  Cancer-Related Fatigue (CRF)                                                                                             Factor                                                                                              
  ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- ---------- -------
  Difficulty completing daily tasks attributed to feeling fatigued                                                         0.855                                                                                               
  Significant diminished energy in daily life or social of functioning                                                     0.811                                                                                               
  Decreased motivation or interest to engage in usual activities                                                           0.768                                                                                               
  Perceived need to struggle to overcome inactivity                                                                        0.750                                                                                               
  Perceived problems with short-term memory                                                                                                                                                                         0.865      
  Diminished concentration or attention                                                                                                                                                                             0.845      
  Complaints of generalized weakness or limb heaviness                                                                                                                                                              0.750      
  Post-exertional malaise lasting several hours                                                                                                                                                                     0.667      
  Hypersomnia                                                                                                                                                                                                                  0.893
  Experience of sleep as unrefreshing or nonrestorative                                                                                                                                                                        0.796
  Cronbach's α:                                                                                                                                                                                                                
   Factor 1 = 0.873                                                                                                        KMO = 0.839, χ^2^ = 541.686[\*\*\*](#table-fn2-1534735418805149){ref-type="table-fn"}               
   Factor 2 = 0.864                                                                                                        Total variance explained 87.8%                                                                      
   Factor 3 = 0.715                                                                                                                                                                                                            
  Fear of Recurrence (FOR)                                                                                                 Factor                                                                                              
  1                                                                                                                        2                                                                                        3          
  Psychological Distress                                                                                                   Lifestyle Function                                                                       Triggers   
  Sadness, discouragement, or disappointment                                                                               0.858                                                                                               
  Worry, fear, or anxiety                                                                                                  0.833                                                                                               
  Helplessness or resignation                                                                                              0.780                                                                                               
  Frustration, anger, or outrage                                                                                           0.779                                                                                               
  I am worried or anxious about the FOR                                                                                    0.774                                                                                               
  I am afraid of a cancer recurrence                                                                                       0.768                                                                                               
  When I think about FOR, other unpleasant thoughts or images come to mind (death, suffering consequences for my family)   0.748                                                                                               
  My social or leisure activities (eg, outings, sports, travel)                                                                                                                                                     0.880      
  My work or everyday activities                                                                                                                                                                                    0.866      
  My relationship with my partner, my family, or those close to me                                                                                                                                                  0.836      
  My quality of life in general                                                                                                                                                                                     0.762      
  My ability to make future plans or set life goals                                                                                                                                                                 0.690      
  Seeing or hearing someone who is ill                                                                                                                                                                                         0.859
  Going to funeral or reading the obituary section of the paper                                                                                                                                                                0.768
  Television shows or newspaper articles about cancer or illness                                                                                                                                                               0.684
  Cronbach's α:                                                                                                                                                                                                                
   Factor 1 = 0.956                                                                                                        KMO = 0.915, χ^2^ = 1254.630[\*\*\*](#table-fn2-1534735418805149){ref-type="table-fn"}              
   Factor 2 = 0.936                                                                                                        Total variance explained 95.4%                                                                      
   Factor 3 = 0.794                                                                                                                                                                                                            

Abbreviations: KMO, Kaiser-Meyer-Olkin.

*P* \< .001

### FOR Scale {#section9-1534735418805149}

The FOR scale was designed based on the Chinese edition of the Fear of Cancer Recurrence Inventory (FCRI) and included 42 items. A 5-point Likert-type scale was utilized for all items used to evaluate the degree of fear of cancer recurrence among the cancer survivors during the past month; higher scores indicated more severe FOR.^[@bibr33-1534735418805149]^ Exploratory factor analysis and verification were performed. The Kaiser-Meyer-Olkin value was 0.915, and Bartlett's test of sphericity yielded χ^2^ = 1254.630 (*P* \< .001). Only 15 questions were retained, and they were categorized into 3 domains: psychological distress, lifestyle function, and triggers. The accumulated variation was 79.073%. The overall Cronbach's α of the internal consistency reliability of the scale was 0.954, suggesting very good reliability and effectiveness. Moreover, within each area, the correlation coefficient of each item was greater than 0.500 after removing the question. The results indicate that the questionnaire was reliable and effective as a measurement tool for evaluating FOR ([Table 1](#table1-1534735418805149){ref-type="table"}).

### QOL Scale {#section10-1534735418805149}

The QOL scale was designed based on the fourth Chinese edition of the Functional Assessment of Cancer Therapy-General (FACT-G) and included 27 items. The original English version contained 28 questions. To improve the internal consistency and stability of the theme, the construct validity factor analysis and verification were performed again. A total of 4 component themes were selected, and the scale was finally reduced to 27 questions, becoming the fourth edition of the Chinese version of the FACT-G scale. A 5-point Likert-type scale was utilized for all items used to examine the level of QOL within the past 7 days. Four domains were included in the scale. The questions of physical and emotional well-being were reverse-scored. Higher scores indicated poorer QOL. For social/family and functional well-being, higher scores indicated higher life functions and better QOL.^[@bibr34-1534735418805149]^

### HRV Indicators {#section11-1534735418805149}

The CheckMyHeart Handel HRV, which has received safety certification from the Food and Drug Administration of the United States and the CE marking of the European Economic Area, was adapted for HRV examination. Participants were asked to avoid foods with intense flavors, smoking, and caffeinated and alcoholic beverages the day before the test.^[@bibr35-1534735418805149]^ The room temperature was maintained at 23°C to 25°C. The participants were seated or lying prone during a 5-minute Lead II electrocardiography recording. The recorded data were converted to HRV indicators using time domain and frequency domain analysis methods as described below:

1.  Standard deviation of normal R-R intervals (SDNN) represents the overall activity of HRV in the time domain; a higher score indicates higher HRV overall activity.

2.  Total power (TP): the clinical meaning of TP in the frequency domain is similar to that of SDNN in the time domain; a lower score indicates a higher level of fatigue, a lack of energy, or a lack of strength.

3.  High frequency (HF) represents the parasympathetic nervous system activity in the frequency domain; a lower score indicates that the subject is experiencing anxiety or stress, whereas a higher score indicates relaxation.

Interventions {#section12-1534735418805149}
-------------

Mind-body support and social support are indispensable components of education and care for cancer patients. The Memorial Sloan-Kettering Cancer Center and the MD Anderson Cancer Center in the United States actively promote mind-body support treatment, and such treatment has become part of the traditional cancer treatment method.^[@bibr36-1534735418805149],[@bibr37-1534735418805149]^ Moreover, provision of balanced nutrition and supplements is considered critical in the care of cancer survivors. Therefore, CRF, FOR, QOL, and HRV were monitored to evaluate the effects of physical and psychological activities as interventions.

### Nutrition Management {#section13-1534735418805149}

Two hours of nutrition management education were provided to the 3 groups of participants by a certified dietitian. Accurate dietary principles were introduced, and dietary habits were adjusted to achieve a balanced diet and to supply adequate nutrition.

### Qigong Exercise {#section14-1534735418805149}

A certified martial arts specialist of the International Wushu Federation taught the method of 12-style QE, including standing position, meditation, and leg massage. The exercises allow enhancement of heart and lung function, facilitate blood and energy circulation, regulate physical functions, allow deep relaxation of the body, and promote self-healing capabilities. Handouts and demonstration DVDs were provided to encourage the participants to practice at home and to improve their skills.

### Stress management {#section15-1534735418805149}

A rehabilitation and mental health counseling professor led the patients in the SM group. The program involved conversation and sharing of cognitive behavior modification and mindfulness decompression for a total of 90 minutes. During the remaining 20 minutes, body relaxation and meditation techniques that patients could use to relieve mental and emotional stress were demonstrated. The cognitive behavior modification process was divided into 3 phases as follows^[@bibr38-1534735418805149]^:

1.  The first phase was "self-observation." During this phase, the patients learned how to perceive their behavior, listen to their inner voice, and develop a new viewpoint on their problems.

2.  The second phase was "starting a new internal dialogue." In this phase, the patients learned to change their inappropriate inner dialogue and were helped restructure their cognition.

3.  The third phase was "learning new skills." In this phase, the patients were taught effective response skills, how to use these skills to deal with pressure in life situations, and how to maintain these skills.

Data Analyses {#section16-1534735418805149}
-------------

The data were analyzed using SPSS 22.0 for Windows (SPSS Inc, Chicago, IL). Chi-square tests were used for comparisons of baseline categorical data among E1, E2, and the control group. The paired sample *t* test was used to compare the improvement effects of single interventions, and 1-way ANOVA was used to analyze the differences in effects among groups. The AR (1) model in the generalized estimating equation was determined to be the best model by QIC (quasi-information criterion) value and was implemented to evaluate correlations among the 3 time points as a basis for assessing improvement over time.

Results {#section17-1534735418805149}
=======

Demographic Characteristics {#section18-1534735418805149}
---------------------------

Among the 80 study participants, there were more females (n = 70) than males (n = 10); the age of the participants ranged from 33 to 75 years, and 47.5% were between 50 and 59 years of age. The cancer survival period ranged from 1.1 to 14.2 years, and 30.1% of the participants had survived for more than 5 years. The most frequent type of cancer among the participants was breast cancer (65%), and most cancers were at stage I or II (72.6%) at diagnosis. A total of 56.3% of the participants felt fatigue, and approximately 25% experienced anxiety or depression. According to baseline (T0) data, almost all participants suffered from CRF (100%) and FOR (98.7%). In total, 77.5% had moderate or severe levels of fatigue, 47.5% suffered from moderate to severe emotional distress, and 7.5% experienced severe fatigue along with a tendency toward emotional distress. With the exception of the survival period, no significant differences in demographic characteristics were found among the 3 groups ([Table 2](#table2-1534735418805149){ref-type="table"}).

###### 

Demographic Characteristics of Participants at Baseline.

![](10.1177_1534735418805149-table2)

                                                                                  Frequency Distribution (%)                                                   
  ------------------------------------------------------------------------------- ---------------------------- ------------ ------------ ------------ -------- ------
  Gender                                                                                                                                              0.705    .703
   Male                                                                           4 (13.8%)                    2 (8.0%)     4 (15.4%)    10 (12.5%)            
   Female                                                                         25 (86.2%)                   23 (92.0%)   22 (84.6%)   70 (87.5%)            
  Age (years)                                                                                                                                         3.848    .871
   30-39                                                                          3 (10.3%)                    1 (4.0%)     1 (3.8%)     5 (6.3%)              
   40-49                                                                          7 (24.1%)                    6 (24.0%)    5 (19.2%)    18 (22.5%)            
   50-59                                                                          11 (37.9%)                   12 (48.0%)   15 (57.7%)   38 (47.5%)            
   60-69                                                                          5 (17.2%)                    5 (20.0%)    3 (11.5%)    13 (16.3%)            
   70-75                                                                          3 (10.3%)                    1 (4.0%)     2 (7.7%)     6 (7.5%)              
  Marital status                                                                                                                                      7.013    .535
   Single                                                                         4 (13.8%)                    3 (12.0%)    5 (19.2%)    12 (15.0%)            
   Married                                                                        23 (79.3%)                   19 (76.0%)   15 (57.7%)   57 (71.3%)            
   Separation                                                                     1 (3.4%)                     1 (4.0%)     1 (3.8%)     3 (3.8%)              
   Divorced                                                                       0 (0.0%)                     1 (4.0%)     4 (15.4%)    5 (6.3%)              
   Widowed                                                                        1 (3.4%)                     1 (4.0%)     1 (3.8%)     3 (3.8%)              
  Education                                                                                                                                           11.041   .199
   Below high school                                                              3 (10.3%)                    1 (4.0%)     6 (23.0%)    10 (12.5%)            
   High school                                                                    6 (20.7%)                    9 (36.0%)    7 (26.9%)    22 (27.5%)            
   College and higher                                                             20 (68.9%)                   15 (60.0%)   13 (50.0%)   48 (60.0%)            
  Survival period                                                                                                                                     12.402   .015
   Within 5 years                                                                 25 (86.2%)                   14 (56.0%)   17 (65.4%)   56 (70.0%)            
   5-10 years                                                                     2 (6.9%)                     11 (44.0%)   6 (23.1%)    19 (23.8%)            
   \>10 years                                                                     2 (6.9%)                     0 (0.0%)     3 (11.5%)    5 (6.3%)              
  Cancer type                                                                                                                                         4.149    .940
   Colorectal cancer                                                              2 (6.9%)                     2 (8.0%)     3 (11.5%)    7 (8.8%)              
   Lung cancer                                                                    1 (3.4%)                     1 (4.0%)     1 (3.8%)     3 (3.8%)              
   Malignant lymphoma                                                             1 (3.4%)                     3 (8.0%)     0 (0.0%)     3 (3.8%)              
   Breast cancer                                                                  18 (62.1%)                   16 (64.0%)   18 (69.2%)   52 (65.0%)            
   Gynecological cancer                                                           2 (6.9%)                     2 (8.0%)     2 (7.7%)     6 (7.5%)              
   Other types of cancer^[a](#table-fn4-1534735418805149){ref-type="table-fn"}^   5 (17.2%)                    2 (8.0%)     2 (7.7%)     9 (11.3%)             
  Cancer staging                                                                                                                         5.097        0.531    
   None stage^[b](#table-fn5-1534735418805149){ref-type="table-fn"}^              1 (3.4%)                     1 (4.0%)     1 (3.8%)     3 (3.7%)              
   I                                                                              7 (24.1%)                    11 (44.0%)   11 (42.3%)   29 (36.3%)            
   II                                                                             15 (51.7%)                   7 (28.0%)    7 (26.9%)    29 (36.3%)            
   III                                                                            6 (20.7%)                    6 (24.0%)    7 (26.9%)    19 (23.8%)            
  Sense of fatigue                                                                                                                                    0.622    .733
   No                                                                             12 (41.4%)                   10 (40.0%)   13 (50.0%)   35 (43.8%)            
   Yes                                                                            17 (58.6%)                   15 (60.0%)   13 (50.0%)   45 (56.3%)            
  Sense of anxiety                                                                                                                                    0.010    .995
   No                                                                             22 (75.9%)                   19 (76.0%)   20 (76.9%)   61 (76.3%)            
   Yes                                                                            7 (24.1%)                    6 (24.0%)    6 (23.1%)    19 (23.8%)            
  Sense of depression                                                                                                                                 1.126    .569
   No                                                                             22 (75.9%)                   17 (68.0%)   21 (80.8%)   60 (75.0%)            
   Yes                                                                            7 (24.1%)                    8 (32.0%)    5 (19.2%)    20 (25.0%)            
  Level of CRF at baseline                                                                                                                            4.188    .381
   None (score of 1-6)                                                            0 (0.0%)                     0 (0.0%)     0 (0.0%)     0 (0.0%)              
   Mild (score of 7-20)                                                           5 (17.2%)                    4 (16.0%)    9 (34.6%)    18 (22.5%)            
   Moderate (score of 21-35)                                                      21 (72.4%)                   20 (80.0%)   15 (57.7%)   56 (70.0%)            
   Severe (score of 36-50)                                                        3 (10.3%)                    1 (4.0%)     2 (7.7%)     6 (7.5%)              
  Level of FOR at baseline                                                                                                                            4.259    .642
   None (score of 1-15)                                                           1 (3.4%)                     0 (0.0%)     0 (0.0%)     1 (1.3%)              
   Mild (score of 16-35)                                                          15 (51.7%)                   11 (44.0%)   15 (57.7%)   41 (51.2%)            
   Moderate (score of 36-55)                                                      10 (34.5%)                   13 (52.0%)   9 (34.6%)    32 (40.0%)            
   Severe (score of 56-75)                                                        3 (10.3%)                    1 (4.0%)     2 (7.7%)     6 (7.5%)              

Abbreviations: E1, Qigong exercise group; E2, stress management group; CRF, cancer-related fatigue; FOR, fear of recurrence.

Other types of cancer including gastric cancer, liver cancer, leukemia, nasopharyngeal carcinoma, and peritoneal mesothelioma.

None stage including leukemia and peritoneal mesothelioma.

Outcome Evaluations {#section19-1534735418805149}
-------------------

### Improvement Effects of Single Interventions {#section20-1534735418805149}

The results of paired sample *t* tests for single interventions are shown in [Table 3](#table3-1534735418805149){ref-type="table"}. After 12 weeks of both QE and SM training (T1 vs T0), CRF was significantly reduced, whereas significant increases were observed for SDNN, TP, and HF. After a 3-month follow-up (T2 vs T0), continuous improvement was observed for CRF (*P* \< .05), but significant decreases (T2 vs T1) were observed for SDNN and TP. Nevertheless, nonsignificant trends toward improvement were observed in FOR and QOL. Although FOR and QOL were not significantly decreased (*P* \> .05), the FOR score was decreased, and the QOL score gradually increased.

###### 

The Paired Sample *t* Test and 1-Way ANOVA of 3 Groups (N = 80).

![](10.1177_1534735418805149-table3)

  Variables   Improvement Effects of Single Interventions^[a](#table-fn7-1534735418805149){ref-type="table-fn"}^   Between-Group Effects^[b](#table-fn8-1534735418805149){ref-type="table-fn"}^                                                                                                                                                                                                                                                                                        
  ----------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ -------- ------------------ ---------------------------------------------------------------- ------ -------------------- ---------------------------------------------------------------- ------- ----------------------------------------------------------------- -------- ------- ------
  CRF                                                                                                                                                                                                                                                                                                                                                                                               1.850                                                             .164     1.416   .249
   E1         −0.213 (0.499)                                                                                       −2.307[\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}                 .029     −0.213 (0.550)     −2.093[\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}   .046   0.000 (0.376)        0.000                                                            1.000                                                                                      
   E2         −0.228 (0.514)                                                                                       −2.216[\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}                 .036     −0.212 (0.506)     −2.095[\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}   .047   0.016 (0.484)        0.165                                                            .870                                                                                       
   Control    0.026 (0.602)                                                                                        0.228                                                                          .822     0.015 (0.640)      0.122                                                            .903   −0.011 (0.554)       −0.106                                                           .916                                                                                       
  FOR                                                                                                                                                                                                                                                                                                                                                                                               0.957                                                             .389     0.750   .476
   E1         −0.147 (0.687)                                                                                       −1.153                                                                         .259     −0.211 (0.751)     −1.516                                                           .141   −0.064 (0.437)       −0.793                                                           .453                                                                                       
   E2         −0.173 (0.495)                                                                                       −1.750                                                                         .093     −0.090 (0.619)     −0.732                                                           .471   0.082 (0.422)        0.979                                                            .337                                                                                       
   Control    0.028 (0.493)                                                                                        0.292                                                                          .773     −0.007 (0.436)     −0.090                                                           .929   −0.035 (0.439)       −0.417                                                           .680                                                                                       
  QOL                                                                                                                                                                                                                                                                                                                                                                                               1.092                                                             .341     0.116   .890
   E1         0.168 (0.587)                                                                                        1.545                                                                          .134     0.026 (0.674)      0.212                                                            .834   −0.141 (0.476)       −1.603                                                           .120                                                                                       
   E2         0.090 (0.386)                                                                                        1.173                                                                          .252     0.078 (0.370)      1.057                                                            .301   −0.012 (0.337)       −0.182                                                           .857                                                                                       
   Control    −0.017 (0.377)                                                                                       −0.240                                                                         .813     0.011 (0.431)      0.140                                                            .890   0.029 (0.284)        0.529                                                            .601                                                                                       
  SDNN                                                                                                                                                                                                                                                                                                                                                                                              9.332[\*\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}   \<.001   0.272   .763
   E1         5.267 (5.657)                                                                                        5.014[\*\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}                \<.001   1.178 (8.217)      0.772                                                            .446   −4.088 (10.036)      −2.194[\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}   .037                                                                                       
   E2         8.390 (5.274)                                                                                        7.954[\*\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}                \<.001   2.369 (11.085)     1.069                                                            .296   −6.021 (10.922)      −2.756[\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}   .011                                                                                       
   Control    −0.881 (11.230)                                                                                      −0.400                                                                         .692     0.140 (12.851)     0.056                                                            .956   1.021 (6.737)        0.773                                                            .447                                                                                       
  TP                                                                                                                                                                                                                                                                                                                                                                                                7.307[\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}     .001     2.129   .126
   E1         203.008 (317.483)                                                                                    3.443[\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}                  .002     47.782 (252.675)   1.018                                                            .317   −155.225 (403.743)   −2.070[\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}   .048                                                                                       
   E2         255.459 (259.103)                                                                                    4.930[\*\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}                \<.001   55.154 (369.998)   0.745                                                            .463   −200.304 (380.110)   −2.635[\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}   .015                                                                                       
   Control    −72.903 (404.670)                                                                                    −0.919                                                                         .367     −9.673 (479.527)   −0.103                                                           .919   63.230 (237.924)     1.355                                                            .188                                                                                       
  HF                                                                                                                                                                                                                                                                                                                                                                                                0.943                                                             .394     0.280   .756
   E1         35.358 (59.786)                                                                                      3.185[\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}                  .004     2.733 (77.064)     0.191                                                            .850   −32.625 (89.502)     −1.963                                                           .060                                                                                       
   E2         34.447 (77.034)                                                                                      2.236[\*\*](#table-fn9-1534735418805149){ref-type="table-fn"}                  .035     18.478 (144.497)   0.639                                                            .529   −15.969 (119.591)    −0.668                                                           .511                                                                                       
   Control    5.365 (124.007)                                                                                      0.221                                                                          .827     29.711 (170.228)   0.890                                                            .382   24.346 (106.030)     1.171                                                            .253                                                                                       

Abbreviations: ANOVA, analysis of variance; T0, baseline; T1, 12-weeks postintervention; T2, 3-month follow-up; CRF, cancer-related fatigue; E1, Qigong exercise group; E2, stress management group; FOR, fear of recurrence; QOL, quality of life; SDNN, standard deviation of normal R-R intervals, the index of overall autonomic nervous system activity; TP, total power, the index of overall activity heart rate variability; HF, high frequency, the index of parasympathetic nerve activity.

Paired sample *t* test.

One-way ANOVA.

*P* \< .01, \*\*\**P* \< .001 (2-tailed test).

The control group received only nutrition guidance. After 12 weeks (T1 vs T0), the control group participants had increased CRF, FOR and decreased QOL, SDNN, and TP. Only HF showed a slight increase (*t* = 0.221, *P* = .827). After 3 months of follow-up (T2 vs T0), FOR, QOL, SDNN, and HF showed gradual improvement; however, the changes were not significant (*P* \> .05), and the participants remained affected by CRF (*t* = 0.122, *P* = .903) and TP (*t* = −0.103, *P* = .919). This result indicates that an appropriate intervention was crucial to managing participants' fatigue, emotional distress, and functional decline in ANS.

### Between-Group Effects {#section21-1534735418805149}

One-way ANOVA between T1 versus T0 and T2 versus T0 showed that there were significant differences between E1, E2, and the control group at T1 in SDNN (T1-T0: F = 9.332, *P* \< .001) and TP (T1-T0: F = 7.307, *P* = .001; [Table 3](#table3-1534735418805149){ref-type="table"}).

### Improvement Over Time {#section22-1534735418805149}

For generalized estimating equation, T0 was specified as the baseline category, and the control group was considered the reference group. At T1, CRF (T1: χ^2^ = 5.344, *P* = .021), SDNN (T1: χ^2^ = 19.682, *P* \< .001), TP (T1: χ^2^ = 10.616, *P* = .001), and HF (T1: χ^2^ = 6.391, *P* = .011) all showed significant improvement (*P* \< .05). CRF (T2: χ^2^ = 4.777, *P* = .029) still showed significant improvement at T2 (*P* \< .05; [Table 4](#table4-1534735418805149){ref-type="table"}).

###### 

Time Effects of 3 Groups From AR1 Model of GEE Analysis (N = 80).

![](10.1177_1534735418805149-table4)

  DV                    IV          Estimate β   SE                                                                  Wald χ^2^                                                            *P*
  --------------------- ----------- ------------ ------------------------------------------------------------------- -------------------------------------------------------------------- --------
  CRF                   Intercept   2.402        0.138                                                               303.075[\*\*\*](#table-fn11-1534735418805149){ref-type="table-fn"}   \<.001
  E1 vs control group   0.173       0.182        0.903                                                               .342                                                                 
  E2 vs control group   0.259       0.161        2.575                                                               .109                                                                 
  T1-T0                 −0.140      0.060        5.344[\*](#table-fn11-1534735418805149){ref-type="table-fn"}        .021                                                                 
  T2-T0                 −0.139      0.635        4.777[\*](#table-fn11-1534735418805149){ref-type="table-fn"}        .029                                                                 
  FOR                   Intercept   2.422        0.143                                                               286.048[\*\*\*](#table-fn11-1534735418805149){ref-type="table-fn"}   \<.001
  E1 vs control group   −0.094      0.185        0.258                                                               .611                                                                 
  E2 vs control group   0.119       0.196        0.364                                                               .546                                                                 
  T1-T0                 −0.098      0.063        2.393                                                               .122                                                                 
  T2-T0                 −0.108      0.068        2.439                                                               .118                                                                 
  QOL                   Intercept   3.953        0.125                                                               997.134[\*\*\*](#table-fn11-1534735418805149){ref-type="table-fn"}   \<.001
  E1 vs control group   −0.014      0.153        0.008                                                               .928                                                                 
  E2 vs control group   −0.062      0.156        0.158                                                               .691                                                                 
  T1-T0                 0.084       0.052        2.595                                                               .107                                                                 
  T2-T0                 0.038       0.056        0.448                                                               .503                                                                 
  SDNN                  Intercept   29.883       2.104                                                               201.597[\*\*\*](#table-fn11-1534735418805149){ref-type="table-fn"}   \<.001
  E1 vs control group   −4.446      2.765        2.585                                                               .108                                                                 
  E2 vs control group   −3.897      2.393        2.651                                                               .103                                                                 
  T1-T0                 4.245       0.956        19.682[\*\*\*](#table-fn11-1534735418805149){ref-type="table-fn"}   \<.001                                                               
  T2-T0                 1.213       1.188        1.043                                                               .307                                                                 
  TP                    Intercept   492.471      72.249                                                              46.462[\*\*\*](#table-fn11-1534735418805149){ref-type="table-fn"}    \<.001
  E1 vs control group   −105.858    91.606       1.335                                                               .248                                                                 
  E2 vs control group   −98.154     78.120       1.579                                                               .209                                                                 
  T1-T0                 129.728     39.815       10.616[\*\*](#table-fn11-1534735418805149){ref-type="table-fn"}     .001                                                                 
  T2-T0                 31.413      41.245       0.580                                                               .446                                                                 
  HF                    Intercept   104.976      20.797                                                              25.479[\*\*\*](#table-fn11-1534735418805149){ref-type="table-fn"}    \<.001
  E1 vs control group   −37.619     26.734       1.980                                                               .159                                                                 
  E2 vs control group   −19.075     27.803       0.471                                                               .493                                                                 
  T1-T0                 25.326      10.018       6.391[\*](#table-fn11-1534735418805149){ref-type="table-fn"}        .011                                                                 
  T2-T0                 16.421      14.800       1.231                                                               .267                                                                 

Abbreviations: AR, autoregressive; GEE, generalized estimating equation; DV, dependent variable; IV, independent variable; SE, standard error; CRF, cancer-related fatigue; E1, Qigong exercise group; E2, stress management group; T0, baseline; T1, 12-week postintervention; T2, 3-month follow-up; FOR, fear of recurrence; QOL, quality of life; SDNN, standard deviation of normal R-R intervals, the index of overall autonomic nervous system activity; TP, total power, the index of overall activity heart rate variability; HF, high frequency, the index of parasympathetic nerve activity.

*P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001 (2-tailed test).

Discussion {#section23-1534735418805149}
==========

The results of this study show that the participants suffered from CRF (100%) and that 77.5% of them experienced moderate to severe fatigue. These findings suggest that the severity of CRF has been underestimated. Cancer survivors are often unaware of this condition; thus, its severity can be overlooked, resulting in delayed treatment. Our findings are consistent with those reported in related studies.^[@bibr5-1534735418805149],[@bibr39-1534735418805149]^

Moreover, 98.7% of the participants displayed emotional distress symptoms due to FOR. Among these participants, 47.5% experienced moderate to severe fear, and 7.5% experienced severe fear. These findings are consistent with the results of related studies in which it was reported that 49% and 7% of cancer survivors suffered from moderate to severe and severe emotional distress, respectively.^[@bibr4-1534735418805149]^ A previous study reported that approximately 50% of cancer survivors experienced a lack of psychological support and care and urgently needed the support provided by social groups and activities.^[@bibr7-1534735418805149]^ Therefore, active participation by the medical staff in providing care and intervention support is critical.

Regarding CRF, QE and SM yielded statistically significant improvements at T1 and T2. QE restores mind-body balance by utilizing breathing exercises, repeated physical movements, and meditation. Symptoms of fatigue can be effectively alleviated, and the improvements can be maintained for a minimum of 3 months.^[@bibr40-1534735418805149]^ Intervention can be achieved by psychological education focused on emotional support, response strategies, and relaxation skills. Moreover, cognitive behaviors were reconstructed, which can actively relieve fatigue and emotional distress and improve problem-solving skills to promote self-efficacy and goal achievement.^[@bibr28-1534735418805149]^ These findings are consistent with the results obtained in our study.

Regarding FOR, a nonsignificant trend toward improvement was noted, but the scores were decreased at T1 and T2, indicating that emotional distress was slightly decreased. Cancer-related emotional distress is different from the distress experienced by healthy individuals. Such distress increases as the cancer survivor ages, as the disease progresses, or as new health issues develop. Moreover, the symptoms of distress can be persistent.^[@bibr41-1534735418805149]^ Symptoms tend to be more severe among females, individuals with lower socioeconomic status, and younger individuals.^[@bibr7-1534735418805149],[@bibr42-1534735418805149]^ Emotional distress has not been correlated with cancer prognosis, survival time, or cancer type. Correlated factors include the level of education received, whether recurrence or metastasis is experienced, and satisfaction with social support.^[@bibr43-1534735418805149]^ Cancer survivors realize the uncertainties in disease progress, health, and QOL. As found in our study, FOR does not decrease with longer survival time or with longer interventions. These findings are consistent with the results of related studies.^[@bibr7-1534735418805149],[@bibr43-1534735418805149]^ Therefore, continuous guidance on physical and psychological activities, nutrition management education, and periodic care should be provided. The fact that 87.5% of the participants in our study were female, a population in which FOR is relatively more severe, might explain the diminished and insignificant intervention effects observed.

Regarding QOL, a nonsignificant trend toward improvement was noted, but the scores were increased at T1 and T2, indicating that QOL was slightly improved. Due to the severe impact of the disease on physical, emotional, and social functions, the QOL of cancer survivors decreases over time. Moreover, the decrease in QOL is more apparent among patients less than 50 years of age. Therefore, long-term care and interventions are necessary.^[@bibr44-1534735418805149]^ Approximately one third of the participants in our study were less than 50 years of age; this could be the main factor contributing to the insignificant effect of interventions on QOL.

Qigong and SM interventions yielded significant differences in HRV at T1 versus T2. They both resulted in improvements in SDNN and TP and also induced parasympathetic nervous system activation (HF). These intervention activities allow the mind-body to enter a relaxed state and promote the regulation of ANS function, resulting in stabilized emotions. Monitoring of mental and physical states through HRV reveals the benefits and effects of Qigong and SM on physical and psychological health in real time. These results are supported by related studies.^[@bibr11-1534735418805149],[@bibr20-1534735418805149],[@bibr21-1534735418805149],[@bibr29-1534735418805149],[@bibr45-1534735418805149],[@bibr46-1534735418805149]^

The results of our study indicated that QE and SM both enhance the physical and psychological functions of cancer survivors. Furthermore, these activities relieve fatigue and ANS functional disorders.

Thus, when facing the uncertainty of cancer progression, patients can respond with a more stable mental status, a positive attitude, and increased confidence. Adjustments in diet and nutritional supplements are also indispensable to cancer survivors. Elimination of bad dietary habits and improvement in nutrition can allow the rapid restoration of physical functions and enhance immunity. Furthermore, facing disease and life with a positive attitude can improve symptoms and physical and mental energy levels.

This study has some limitations. Regarding effects over time, the effects during the follow-up phase (T2) were not as significant as the immediate effects at T1; however, the improvements were steadily maintained. Although demonstration DVDs and CDs were provided to the participants to encourage home practice, lack of persistence can result from lack of supervision and peer encouragement. We suggest that cancer survivors actively participate in long-term physical and psychological rehabilitation activities. Continuous and periodic involvement in practices led by professional coaches at a minimum frequency of once a week is recommended. Long-term educational resources and care should be provided to maintain long-term improvements. These suggestions are provided herein as a reference for clinical practice. Moreover, significant differences between groups were not observed. Such results may be attributed to the different nature of the interventions; QE emphasizes training in physical strength, whereas SM focuses on mental support. These interventions both yielded improvements. Hence, care should be taken to cultivate both mental and physical health, as they complement each other. In future studies, a crossover design is recommended to permit accurate evaluation of the significant effects of the interventions. Moreover, such a design will allow the survivors to receive both physical and psychological support, as cancer patients can benefit from both activities.

Conclusion {#section24-1534735418805149}
==========

In our study, questionnaires and HRV were employed to evaluate the condition of cancer survivors during recovery. The results suggest that QE and SM affect HRV in addition to CRF, which is an interesting finding on its own. Although the questionnaires employed were reliable and effective, the responses were based on subjective opinions and personal feelings and may not truly reflect the mental and physical health of cancer survivors. In contrast, HRV provides effective monitoring of heart and lung function and the status of ANS balance. Because the progress of cancer patients can be monitored easily and rapidly with HRV, this approach can serve as an indicator for evaluating the mind-body state after treatment and can assist medical providers in providing comprehensive care. Providing scientific support for the effectiveness of HRV is the focus of our future study.
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